Pharmaceutical News

RSS

Experimental sleep drug eszopiclone helps elderly to sleep better

Older people with insomnia slept better and longer after taking an experimental sleep medication, according to research at Wake Forest University Baptist Medical Center.

6 May 2004

New guidelines for using new antiepileptic drugs to treat epilepsy

The number of drugs available to treat epilepsy have more than doubled in the last decade. The American Academy of Neurology and the American Epilepsy Society have assembled the top experts in the field to evaluate the available data of 1,462 research articles in order to create a guideline for the treatment of epilepsy with the new antiepileptic drugs (AEDs).

6 May 2004

Ritalin drug used to treat hyperactive children boosts the potency of Parkinson's drug levodopa

A well-known drug used to treat hyperactive children boosts the potency of another drug that reduces Parkinson's disease symptoms, an Oregon Health & Science University study has found.

6 May 2004

Medicare says drug discount program shows savings up to 17 percent for brand name drugs

The first analysis comparing the Medicare-approved drug discount cards with the current prices for prescription medicines shows savings of at least 10 to 17 percent for brand name drugs and far larger savings for generic drugs

6 May 2004

FDA approval of Hylaform and Restylane, both injectable gels, to treat facial wrinkles

The list of cosmetic soft tissue fillers on the market and in the pipeline worldwide is growing rapidly. Many have been introduced with great fanfare; relatively few stand the test of regulatory or peer review - as well as the test of time.

6 May 2004

Immtech signs agreement with CombinatoRx to test Immtech compounds as potential cancer treatment

Immtech International, Inc. announced today that it signed an agreement with CombinatoRx of Boston, Massachusetts to screen its lead aromatic cationic compounds, DB289 and DB75, for activity against various cancers.

5 May 2004

Trial of antibody for HIV Infection

Tanox, Inc. announced today that it has begun dosing patients in its Phase 2 clinical trial of TNX-355 for the treatment of the human immunodeficiency virus (HIV).

5 May 2004

Agreement expands Quintiles capabilities to support drug approvals in Japan

Quintiles Transnational Corp. today announced an agreement to conduct clinical trials in Peru involving ethnic Japanese, further expanding the company's ability to support new drug applications in Japan.

5 May 2004

Mylan announces FDA approval of Parkinson’s disease drug

The FDA approval clears the way for Bertek to market APOKYN and provides a new therapy for “off” episodes, one of the most debilitating aspects suffered by patients with Parkinson’s disease.

5 May 2004

First canine insulin drug

FDA has approved a porcine insulin zinc suspension product as the first drug for treating diabetic dogs. Prior to the development of this product, the only treatment veterinarians could use on diabetic dogs was human insulin, which is less compatible with a dog’s metabolic system.

4 May 2004

UK researchers get 180,000 Euros to identify and develop new vaccines against Tuberculosis

A researcher from Birmingham University's School of Biosciences has won EU funding of 180,000 Euros to identify and develop new vaccines against Tuberculosis.

4 May 2004

New license agreement for rotavirus diarrhea vaccine

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), announced today a new license agreement aimed at helping to prevent hundreds of thousands of deaths annually from rotavirus diarrhea in children living in developing countries.

4 May 2004

Pfizer targets five internet sites for selling an unapproved copy of Pfizer's top selling cholesterol medicine, Lipitor

Pfizer has filed lawsuits against the operators of five internet sites for selling an unapproved copy of Pfizer's top selling cholesterol medicine, Lipitor, the company said today.

4 May 2004

First drug product for treatment of short bowel syndrome

Short bowel syndrome (SBS) is a rare and potentially life-threatening condition in which the ability of the small intestine to absorb the nutrition a person needs from food is impaired. Short bowel syndrome can occur after surgical removal of part of the intestine, due to trauma or because the intestine is diseased.

4 May 2004

FDA to create database to help identify counterfeit pharmaceutical brands

The US Food and Drug Administration (FDA) is planning to create a database of the major pharmaceutical brands on the US market, to make it easier to establish the authenticity of suspect products and identify counterfeit versions that enter the supply chain.

3 May 2004

Schering-Plough Corporation settles with $27 million to the State of Texas

Schering-Plough Corporation has announced that it has reached an agreement with the Attorney General's Office of the State of Texas to settle issues related to reimbursement by Texas' Medicaid program of albuterol sulfate solution and inhaler products.

3 May 2004

Australian company receives FDA orphan drug designation for product to treat malignant melanomas

Progen Industries Limited, an Australian anti-cancer drug development company, announced today that it has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for their lead anti-angiogenesis product PI-88 for treatment of malignant melanoma.

3 May 2004

America’s Health Insurance Plans to provide drug discount cards to Medicare beneficiaries

Karen Ignagni, President and CEO of America's Health Insurance Plans (AHIP), made the following statement regarding HHS Secretary Tommy G. Thompson's announcement today of the start of the prescription drug card program:

3 May 2004

Pharmacy Care Alliance set to begin marketing to Medicare beneficiaries

The Pharmacy Care Alliance today announced that it received approval from Medicare to begin education, outreach and enrollment activities for its Medicare-approved drug discount card on May 3.

3 May 2004

Cymbalta helped patients with depression feel better

Patients treated successfully with 60 mg per day of the investigational antidepressant Cymbalta® (duloxetine hydrochloride), were less likely to have their emotional and physical symptoms of depression return than those who stopped taking medication after beginning to feel better

3 May 2004

Pharmaceutical News

Experimental sleep drug eszopiclone helps elderly to sleep better

New guidelines for using new antiepileptic drugs to treat epilepsy

Ritalin drug used to treat hyperactive children boosts the potency of Parkinson's drug levodopa

Medicare says drug discount program shows savings up to 17 percent for brand name drugs

FDA approval of Hylaform and Restylane, both injectable gels, to treat facial wrinkles

Immtech signs agreement with CombinatoRx to test Immtech compounds as potential cancer treatment

Trial of antibody for HIV Infection

Agreement expands Quintiles capabilities to support drug approvals in Japan

Mylan announces FDA approval of Parkinson’s disease drug

First canine insulin drug

UK researchers get 180,000 Euros to identify and develop new vaccines against Tuberculosis

New license agreement for rotavirus diarrhea vaccine

Pfizer targets five internet sites for selling an unapproved copy of Pfizer's top selling cholesterol medicine, Lipitor

First drug product for treatment of short bowel syndrome

FDA to create database to help identify counterfeit pharmaceutical brands

Schering-Plough Corporation settles with $27 million to the State of Texas

Australian company receives FDA orphan drug designation for product to treat malignant melanomas

America’s Health Insurance Plans to provide drug discount cards to Medicare beneficiaries

Pharmacy Care Alliance set to begin marketing to Medicare beneficiaries

Cymbalta helped patients with depression feel better

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News